A look at the hot topics expected to dominate this year’s conference in Boston.
This page is available to everyone for download.
Doctors performed more than 3.7 million implantations in 2013.
News coverage scrutinized payments of nearly $1 billion for Lucentis treatments for patients with retinal disease.
The meeting was designed to identify challenges in lens innovation.
New rules include the creation of a publicly accessible database of all results.
Clinical trials will further evaluate the efficacy and safety of the vitreolytic.
Market is somewhat out of step with generally improving economic conditions.
Annual procedure volume expected to increase from 3.4 million to 4.3 million.
Jeff George will be the sixth executive to lead Alcon in its almost 70-year history.
The 12-month patch will extend the current 0.5 percent increase through 2014.
Legislation that delays implementation contains vague wording for new start date.
You are not currently logged in.
©2017 Market Scope
Lost your Password